A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …

Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …

Background Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of
oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that …

Background There is an unmet need to develop therapeutic interventions directed at the
neurodegeneration that underlies progression in multiple sclerosis. High-dose …

Objective To test the hypothesis that immunotherapy prevents long-term disability in
relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 …

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis;
however, treatment response varies greatly among patients. Comprehensive predictive …

Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …

Background: The risk factors for conversion from relapsing-remitting to secondary
progressive multiple sclerosis remain highly contested. Objective: The aim of this study was …

Objective To investigate pregnancy-related disease activity in a contemporary multiple
sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included …